Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2020

01-06-2020 | Metastasis | Peritoneal Surface Malignancy

The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases

Author: Chicago Consensus Working Group

Published in: Annals of Surgical Oncology | Issue 6/2020

Login to get access

Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of gastric cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
Literature
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
12.
Hu YF, Deng ZW, Liu H, et al. Staging laparoscopy improves treatment decision-making for advanced gastric cancer. World J Gastroenterol. 2016;22(5):1859–1868.CrossRef
13.
Muntean V, Mihailov A, Iancu C, et al. Staging laparoscopy in gastric cancer: accuracy and impact on therapy. J Gastrointestin Liver Dis. 2009;18(2):189–195.PubMed
14.
Fujimura T, Kinami S, Ninomiya I, et al. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer. Endoscopy. 2002;35:569–574.CrossRef
15.
Bernards N, Creemers GJ, Nieuwenhuijzen GA, Bosscha K, Pruijt JF, Lemmens VE. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24(12):3056–3060.CrossRef
16.
Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–1581.CrossRef
17.
Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251(4):640–646.CrossRef
18.
Noguchi Y, Yoshikawa T, Tsuburaya A, Motohashi H, Karpeh MS, Brennan MF. Is gastric carcinoma different between Japan and the United States? Cancer. 2000;89(11):2237–2246.CrossRef
19.
Bonnot PE, Piessen G, Kepenekian V, et al; FREGAT and BIG-RENAPE Networks. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028–2040.
20.
Glehen O, Gilly FN, Arvieux C, et al; Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–2377.
21.
Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(7):911–919.
22.
Yonemura Y, Elnemr A, Endou Y, et al. Surgical results of patients with peritoneal carcinomatosis treated with cytoreductive surgery using a new technique named aqua dissection. Gastroenterol Res Pract. 2012;2012:521487.PubMedPubMedCentral
23.
Königsrainer I, Horvath P, Struller F, Königsrainer A, Beckert S. Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer. 2014;14(2):117–122.CrossRef
24.
Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005;92(3):370–375.CrossRef
25.
Fujitani K, Yang H-K, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–318.CrossRef
26.
Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
27.
Shirao K, Boku N, Yamada Y, et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43(10):972–980.
28.
Yonemura Y, Canbay E, Yoshio E, et al. Comprehensive treatment for the peritoneal metastasis from gastric cancer. World J Surg Proc. 2015;5(2):187–197.CrossRef
29.
Badgwell B, Blum M, Das P, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24(11):3338–3344.CrossRef
30.
Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138(1):26–33.CrossRef
31.
Yonemura Y, Bandou E, Kinoshita K, et al. Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am. 2003;12(3):635–648.CrossRef
Metadata
Title
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases
Author
Chicago Consensus Working Group
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08320-0

Other articles of this Issue 6/2020

Annals of Surgical Oncology 6/2020 Go to the issue

Melanoma

Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?

Hepatobiliary Tumors

Dedicated Cancer Centers are More Likely to Achieve a Textbook Outcome Following Hepatopancreatic Surgery

Hepatobiliary Tumors

Elevated Serum α-Fetoprotein is Associated with Abbreviated Survival for Patients with Fibrolamellar Hepatocellular Carcinoma Who Undergo a Curative Resection

Hepatobiliary Tumors

A Translational Approach to Standardization of Machine Perfusion Adoption in Ex Vivo Liver Resection

Health Services Research and Global Oncology

Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations

Translational Research and Biomarkers

PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer